Analysis of the Value of Combined Detection of Serum miR-302a-3p and Low Density Lipoprotein Cholesterol in the Diagnosis of Coronary Heart Disease

Abstract

The diagnosis of premature coronary heart disease (PCHD) continues to pose challenges. miR-302a-3p serves as a potential diagnostic marker. This study investigated the diagnostic value of the combination serum miR-302a-3p and LDL-C for PCHD. This study encompassed a total of 116 patients with coronary artery stenosis (CAS), 116 patients with PCHD, and 108 control subjects. The levels of miR-302a-3p, TNF, IL6, and IL1B were detected by RT-qPCR. ROC curves and logistic regression analysis were used to evaluate diagnostic value and risk factors for disease progression, respectively. In vitro models of HUVECs were established by treating the cells with ox-LDL. Cell proliferation and apoptosis were detected by CCK-8 and flow cytometry, respectively. SOD and MDA were assessed using commercial kits. Serum levels of miR-302a-3p and LDL-C were increased in both the CAS and PCHD groups. miR-302a-3p, LDL-C, Apo B-100, and Gensini scores are independent risk factors for the progression of CAS to PCHD. The AUC of the combined diagnostic model of miR-302a-3p and LDL-C for differentiating PCHD from the control group was 0.902, whereas the diagnostic value of miR-302a-3p alone was 0.885. In cellular experiments, inhibition of miR-302a-3p can mitigate the release of inflammatory factors and oxidative stress induced by ox-LDL. miR-302a-3p serves as an independent risk factor for PCHD. The combination of miR-302a-3p with LDL-C can significantly enhance the accuracy of diagnostic value. miR-302a-3p may participate in the pathological process of PCHD, and its function is related to inflammatory responses and oxidative stress.